Navigation Links
Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
Date:5/28/2009

Proteon also receives orphan drug designation for its lead product candidate, PRT-201

WALTHAM, Mass., May 28 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has completed a second closing of its Series B equity financing, securing an additional $12 million and increasing the total equity capital raised in this round to $50 million. The additional equity investment came primarily from two new investors, Bessemer Venture Partners and Devon Park Bioventures, as well as from previous investors. Proteon also disclosed its lead product candidate, PRT-201, received orphan drug designation from FDA for prevention of arteriovenous fistula (AVF) maturation failure and arteriovenous graft (AVG) failure in patients with end-stage renal disease who are on or preparing for hemodialysis. Orphan drug designation allows for certain tax credits and an extended period of data exclusivity. These new developments follow Proteon's recent announcement of an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201, with a potential secondary right to a global license under pre-agreed conditions.

"We are very pleased and fortunate to add the outstanding firms of Bessemer and Devon Park to our existing syndicate of blue chip investors," said Timothy P. Noyes, President and CEO of Proteon.

The initial closing of the Series B financing in March included new investors MPM Bio IV NVS Strategic Fund L.P. and Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Earlier this year, Proteon initiated a Phase 1/2 human clinical study of PRT201 in patients undergoing surgery for AVF creation. The combination of the Novartis option agreement and the now increased size o
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
2. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
3. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
4. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
5. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
6. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
9. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
10. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... HOUSTON, Dec. 3 JourneyLite of Houston, LLC ... to offer patients a second surgical option, vertical ... that it currently performs. The first sleeve gastrectomy ... Matthew St. Laurent, MD on October 20, ...
(Date:12/3/2009)... Shire plc (LSE: SHP, Nasdaq: SHPGY ), the ... of five lots and voluntary market withdrawal of one ... . Shire is taking this action because some Daytrana ... not meet their release liner removal specification, and as ...
(Date:12/3/2009)... Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at ... spoke at a conference on High-Risk Diabetic,Foot Care ... is China,s leading,stem cell research and regenerative medicine ... organized by the Indian Podiatry Association (IPA), aimed,to ...
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com announces ... available in its catalogue: ,, Carbondioxide ... ,, http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators ... microbiology, genetics, cancer, research, and other applications ...
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... ) announced today that an Australia/New Zealand-focused clinical evaluation of its ... in a self-expanding frame, was initiated last week. , ... ... The first four procedures using the CoreValve ReValving System were ...
... TITUSVILLE, N.J., Aug. 28 Ortho-McNeil Neurologics,Division ... appeal yesterday,s decision by the U.S. District ... RAZADYNE(R) (galantamine hydrobromide) is,invalid., The decision ... to enter the U.S. marketplace "at risk" ...
... inspired by historic,Philadelphia, Pa. and revel in the ... room rate while you discover best practices and ... Hewlett-Packard,Johnson & Johnson, Motorola, Nortel, Roche, Sanofi-Aventis and ... Excellence Conference: How Process,Improvement Leaders Produce Profits in ...
Other Biology Technology: CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries 2Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R) 2Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R) 3Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions 2
(Date:12/3/2009)... past three years in the troposphere (lower atmosphere) over ... which are the first of their kind in the ... 2002 and 2005. , Over recent years, physicists and ... dioxide (CO2) levels, and how these have evolved in ...
(Date:12/3/2009)... UPTON, NY A team of scientists from the ... University, and the Indian Institute of Science has made ... genetic information in DNA that is necessary to carry ... December 1, 2009 edition of Nature Structural & ...
(Date:12/2/2009)... to secondhand cigarette smoke have an increased risk of developing ... , Results of this study are published in Cancer ... Association for Cancer Research, as part of a special tobacco ... more than 219,000 Americans will be diagnosed with lung cancer; ...
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 1New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 2Capital BlueCross Reaches Out to Former Employees of Turbine Airfoil Designs 59319 1Capital BlueCross Reaches Out to Former Employees of Turbine Airfoil Designs 59319 2
... first time the ability to create 3-D positron ... and "fly-around viewing" of cancer in the lungs ... July issue of the Journal of Nuclear Medicine. ... with accurate anatomical information of possible cancerous tumors--from ...
... of people while they walk, researchers have improved our understanding ... at the same time, the researchers found that the stimulus ... who was walking straight ahead to be steered by "remote ... by Richard Fitzpatrick and Jane E. Butler of the Prince ...
... (UC) researchers say exposure to a certain group of ... day--can make young children more susceptible to developing multiple ... that infants who were exposed to basidiospores and other ... more likely to develop allergies to mold, pollen, dust ...
Other Biology News:Coming soon: 3-D imaging that flies 'through' and 'around' cancer 2Coming soon: 3-D imaging that flies 'through' and 'around' cancer 3Stimulation of the semicircular canals can artificially control human walking and balance 2Airborne mold spores increase kids' risk for multiple allergies 2
... ZMD.283. Immunogen: Fusion protein derived ... for ASIP/PAR-3 (atypical PKC isotype-specific interacting ... is not related to the protease-activated-receptors ... Dog Xenopus (positive controls: Caco-2 MDCK ...
...
Request Info...
normal rat IgM AF647...
Biology Products: